Clinical Trial

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Study acronym: CERTIS1
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2027-11-01 -> 2028-02-07 2026-08-13
minor Completion pushed: 2027-11-01 -> 2028-02-07 2026-08-13
notable Primary completion pushed: 2027-08-11 -> 2027-10-13 2026-05-06
minor Completion pushed: 2027-08-11 -> 2027-10-13 2026-05-06
Trial Details
NCT Number NCT05417594
Lead Sponsor AstraZeneca
Conditions Advanced Solid Malignancies
Enrollment 695 participants
Start Date 2022-06-24
Primary Completion 2028-02-07 (estimated)
Study Completion 2028-02-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-12